CIPLA News Today

Cipla Ltd Share Price

CIPLA

CMP as on 02-Jul-24 12:00
₹ 1,489

icon 9.55 | 0.65%

Open
₹ 1,480
Turnover(lac)
₹ 17,744
Prev. Close
₹ 1,479.10
Day's Vol (shares)
₹ 1,191,962
Day's Vol (shares)
₹ 1,479.25         ₹ 1,492.75

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
Article Image

Cipla's Patalganga plant gets Voluntary Action Indicated (VAI) from USFDA

From March 28 to April 4, 2024, the US drug regulator conducted a normal current Good Manufacturing Practices (cGMP) inspection at the site.

  • 25 Jun, 2024 |
  • 1:31 PM
Article Image

Cipla to invest Euro 3 million Ethris

Cipla stated in an exchange statement that this extra investment, made through a convertible loan, will accelerate the company's engagement in the mRNA space.

  • 19 Jun, 2024 |
  • 11:26 AM
Image not found

Cipla gets USFDA approval for its generic acromegaly drug

Lanreotide Injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.

  • 23 May, 2024 |
  • 12:27 PM
Image not found

Cipla to invest Rs 26 crore in Achira Labs' preference shares

Cipla primarily develops drugs to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, etc.

  • 16 May, 2024 |
  • 1:02 PM
Image not found

Cipla promoters may sell up to 2.53% of their stake today

On May 10, Cipla announced a 10% increase in revenue to ₹6,163 Crore and a 79% increase in fourth-quarter profit to ₹939 Crore.

  • 15 May, 2024 |
  • 9:48 AM
Image not found

Cipla Buys Ivia Beaute's Beauty Brands for Rs 130 Crore

The deal is anticipated to close within 60 days after the BTA's signature, or on a later date that the parties have mutually agreed upon in writing.

  • 16 Apr, 2024 |
  • 11:04 AM
Image not found

Q3FY24 Review: Cipla: Advair/Abraxane delay partly offset by Peptides

Recommendation: Add; Target price: Rs 1345

  • 29 Jan, 2024 |
  • 12:29 PM
Article Image

Cipla’s Samina Hamied quits as executive vice chairperson due to personal commitments

The corporation claimed "personal and family commitments" as the reason for her departure from her present post.

  • 29 Jan, 2024 |
  • 12:23 PM
Article Image

Cipla reports 32% y-o-y growth in net profit to Rs 1,056 crore; stock climbs to new 52-week

Its sales for the quarter increased 13.7% YoY to Rs 6,604 crore

  • 23 Jan, 2024 |
  • 10:11 AM
Image not found

Cipla-led arm recalls one lot of Vigabatrin owing to seal intergrity issue

An improper pouch seal may cause powder mix to leak outside the pouch

  • 11 Dec, 2023 |
  • 11:41 AM